Physicians' Academy for Cardiovascular Education

Reduced cardiac adipose tissue by GLP-1RA in T2DM

News - Oct. 4, 2021

Liraglutide reduces cardiac adipose tissue in type 2 diabetes: results from the LiraFlame randomized controlled trial

Presented at the EASD 2021 by: Tine Willum Hansen, MD – Gentofte, Denmark

Introduction and methods

Cardiac adipose tissue encloses the heart. An increased amount of adipose tissue has been associated with increased risk of CV events.

The mechanisms of CV benefit with some members of the GLP-1RA class are unclear. The GLP-1 receptors are expressed in cardiac adipose tissue, and may mediate the cardioprotective effects observed with GLP-1RAs.

For this study, data of the LIRAFLAME trial were used. The LIRAFLAME trial was a randomized, double-blind, placebo-controlled trial that examined the effect of liraglutide on vascular inflammation compared to placebo in 102 patients with T2DM at week 26. In this trial, liraglutide did not change vascular inflammation.

In this analysis, change in cardiac adipose tissue measured by CT was assessed.

Main results


Treatment with the GLP-1RA liraglutide for 26 weeks reduced cardiac adipose tissue compared to placebo in patients with T2DM. This reduction was dependent of weight loss, suggesting that this was not a drug-specific effect.

- Our reporting is based on the information provided at the EASD Virtual Meeting–

The findings of this study were simultenously published in Diabetes, Obesity and Metabolism

Share this page with your colleagues and friends: